Back to results
US 2021/0220295 A1Published application
Treatment of cancer by guanidinium derivatives
AssigneeUcar Health GmbH
InventorDilek UCAR
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUcar Health GmbH
InventorDilek UCAR
Estimating the term…
The present invention relates to a combination therapy for the treatment of cancer, particularly to combinations of oligo(2-(2-ethoxy)ethoxy ethyl guanidinium chloride), poly(hexamethylendiamine guanidiniumchloride), polyetheramines, triethyleneglycol diamine, enzymes, PGPR, amino acids, antioxidants like humic acids and some natural products like phytotherapeutic plant extracts. The combination therapy of the present invention shows enhanced anti-cancerous therapeutic effects compared to the effect of each of the components administered alone. In some embodiments, the combination therapy provide for a synergistic anti-cancer effect. A liposomal drug composition comprising; A dimeric or polymeric guanidine derivative or polyetheramines, triethyleneglycol diamine, enzymes, PGPR, amino acids, antioxidants like humic acids and some natural products like phytotherapeutic plant extracts a pharmaceutically acceptable salt thereof as drug substance, and a lipid modified by polyethylene glycole (PEG).
A method for the treatment of cancer in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of oligo(2-(2-ethoxy)ethoxy ethyl guanidinium chloride), poly(hexamethylendiamine guanidiniumchloride), polyetheramines, Triethyleneglycol diamine, enzymes, PGPR, amino acids, antioxidants like humic acids and some natural products like phytotherapeutic plant extracts, wherein said therapeutically effective amount of said compound is about 15-25 mg per kg body weight per day and has a lethal effect on cells of said cancer, and wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, pancreatic cancer, ovarian cancer, glioblastoma and leukemia.
Liposomal drug composition containing:
The method of claim 48, wherein the at least one additional anti-cancer agent is a PGPR, Plant Growth Promoting Rhizobacteria, said biological agent is an antibody selected from the group consisting of Acinetobacter, Achromobacter, Aereobacter, Agrobacterium, Alcaligenes, Artrobacter, Azospirillum, Serratia, Bacillus, Burkholderia, Enterobacter, Erwinia, Flavobacterium, Microccocus, Pseudomonas, Rhizobium ve Xanthomonas.
Dependencies are inferred from the claim text.